Literature DB >> 1967457

Plasma CGRP in acute myocardial infarction.

J Mair, P Lechleitner, T Längle, C Wiedermann, F Dienstl, A Saria.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 1967457     DOI： 10.1016/0140-6736(90)90040-c

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  13 in total

1.  CGRP receptors mediating CGRP-, adrenomedullin- and amylin-induced relaxation in porcine coronary arteries. Characterization with 'Compound 1' (WO98/11128), a non-peptide antagonist.

Authors:  P Hasbak; A Sams; S Schifter; J Longmore; L Edvinsson
Journal:  Br J Pharmacol       Date:  2001-08       Impact factor: 8.739

2.  Non-competitive antagonism of amylin on CGRP(1)-receptors in rat coronary small arteries.

Authors:  M Sheykhzade; N C Nyborg
Journal:  Br J Pharmacol       Date:  2000-05       Impact factor: 8.739

Review 3.  The role of neuropeptides in adverse myocardial remodeling and heart failure.

Authors:  Alexander Widiapradja; Prasad Chunduri; Scott P Levick
Journal:  Cell Mol Life Sci       Date:  2017-01-17       Impact factor: 9.261

4.  Possible role of diadenosine polyphosphates as modulators of cardiac sensory-motor neurotransmission in guinea-pigs.

Authors:  A Rubino; G Burnstock
Journal:  J Physiol       Date:  1996-09-01       Impact factor: 5.182

5.  Inhibition of capsaicin-induced increase in dermal blood flow by the oral CGRP receptor antagonist, telcagepant (MK-0974).

Authors:  Simon R Sinclair; Stefanie A Kane; Bart J Van der Schueren; Alan Xiao; Kenneth J Willson; Janet Boyle; Inge de Lepeleire; Yang Xu; Lisa Hickey; William S Denney; Chi-Chung Li; John Palcza; Floris H M Vanmolkot; Marleen Depré; Anne Van Hecken; M Gail Murphy; Tony W Ho; Jay N de Hoon
Journal:  Br J Clin Pharmacol       Date:  2010-01       Impact factor: 4.335

Review 6.  Calcitonin gene-related peptide: physiology and pathophysiology.

Authors:  F A Russell; R King; S-J Smillie; X Kodji; S D Brain
Journal:  Physiol Rev       Date:  2014-10       Impact factor: 37.312

Review 7.  Heteroreceptors Modulating CGRP Release at Neurovascular Junction: Potential Therapeutic Implications on Some Vascular-Related Diseases.

Authors:  Abimael González-Hernández; Bruno A Marichal-Cancino; Jair Lozano-Cuenca; Jorge S López-Canales; Enriqueta Muñoz-Islas; Martha B Ramírez-Rosas; Carlos M Villalón
Journal:  Biomed Res Int       Date:  2016-12-27       Impact factor: 3.411

8.  A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Erenumab on Exercise Time During a Treadmill Test in Patients With Stable Angina.

Authors:  Christophe Depre; Lubomir Antalik; Amaal Starling; Michael Koren; Osaro Eisele; Robert A Lenz; Daniel D Mikol
Journal:  Headache       Date:  2018-05       Impact factor: 5.887

9.  Phase 1, randomized, parallel-group, double-blind, placebo-controlled trial to evaluate the effects of erenumab (AMG 334) and concomitant sumatriptan on blood pressure in healthy volunteers.

Authors:  Jan de Hoon; Anne Van Hecken; Corinne Vandermeulen; Marissa Herbots; Yumi Kubo; Ed Lee; Osa Eisele; Gabriel Vargas; Kristin Gabriel
Journal:  Cephalalgia       Date:  2018-05-21       Impact factor: 6.292

10.  Renal denervation attenuates aldosterone expression and associated cardiovascular pathophysiology in angiotensin II-induced hypertension.

Authors:  Mo-Na Hong; Xiao-Dong Li; Dong-Rui Chen; Cheng-Chao Ruan; Jian-Zhong Xu; Jing Chen; Yong-Jie Wu; Yu Ma; Ding-Liang Zhu; Ping-Jin Gao
Journal:  Oncotarget       Date:  2016-10-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.